KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $166.9 million.

  • Biogen's Deferred Taxes rose 38578.77% to $166.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $361.6 million, marking a year-over-year increase of 32871.6%. This contributed to the annual value of $361.6 million for FY2025, which is 32871.6% up from last year.
  • According to the latest figures from Q4 2025, Biogen's Deferred Taxes is $166.9 million, which was up 38578.77% from $253.8 million recorded in Q3 2025.
  • Biogen's 5-year Deferred Taxes high stood at $323.3 million for Q4 2021, and its period low was -$607.8 million during Q2 2021.
  • Its 5-year average for Deferred Taxes is -$34.9 million, with a median of -$39.9 million in 2022.
  • As far as peak fluctuations go, Biogen's Deferred Taxes skyrocketed by 61399.05% in 2021, and later tumbled by 655000.0% in 2023.
  • Over the past 5 years, Biogen's Deferred Taxes (Quarter) stood at $323.3 million in 2021, then crashed by 108.91% to -$28.8 million in 2022, then skyrocketed by 349.65% to $71.9 million in 2023, then crashed by 181.22% to -$58.4 million in 2024, then soared by 385.79% to $166.9 million in 2025.
  • Its Deferred Taxes was $166.9 million in Q4 2025, compared to $253.8 million in Q3 2025 and -$31.3 million in Q2 2025.